AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
Last trade$292.73
Day change-$1.82 (-0.62%)
Day range$290.81 – $296.22
Volume1,690,047
Market cap$520.65B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$520.65B
Price / earnings
50.39×
Price / book
-113.6×
Price / sales
7.89×
EV / sales
8.95×
EV / EBITDA
18.94×
Profitability
Earnings per share
$5.85
Return on assets
7%
Return on equity
-225.44%
Dividend yield
2.33%
Liquidity and leverage
Debt / equity
-17.65×
Current ratio
0.87×
Quick ratio
0.75×
Cash ratio
0.25×
Cash flow
Price / cash flow
25.92×
Price / free cash flow
27.59×
Free cash flow
$18.87B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ABBV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$17.4B
$16.99B
$15B
$16.62B
$15.78B
$15.42B
$13.34B
$15.1B
Cost of revenue
$4.29B
$4.29B
$4.22B
$4.55B
$5.3B
$4.35B
$4B
$4.4B
Gross profit
$13.12B
$12.7B
$10.78B
$12.07B
$10.47B
$11.08B
$9.34B
$10.71B
Selling, general and administrative
$4.09B
$3.63B
$3.58B
$3.9B
$3.57B
$3.25B
$3.29B
$3.86B
Research and development
$2.57B
$2.34B
$2.47B
$2.58B
$2.32B
$2.13B
$2.07B
$6.77B
Total operating expenses
$6.85B
$6.27B
$6.79B
$7.74B
$8.57B
$6.18B
$5.61B
$12.2B
Operating income
$6.27B
$6.43B
$3.99B
$4.33B
$1.9B
$4.89B
$3.73B
-$1.5B
Interest expense
-$700M
-$679M
$0
$0
-$667M
-$678M
$0
$0
Income before taxes
$4.83B
$4.28B
$1.04B
$2.67B
$714M
$1.55B
$1.66B
-$2.27B
Income taxes
$609M
$662M
$342M
$853M
$526M
$613M
$372M
-$2.25B
Net income
$4.22B
$3.62B
$697M
$1.82B
$188M
$941M
$1.29B
-$23M
Net income attributable to common shareholders
$4.22B
$3.61B
$695M
$1.81B
$186M
$938M
$1.29B
-$32M
EBITDA
$8.34B
$8.61B
$6.67B
$7.58B
$6.65B
$7.77B
$6.02B
$2.18B
Basic earnings per share
$2.38
$2.04
$0.39
$1.02
$0.10
$0.52
$0.72
-$0.02
Diluted earnings per share
$2.37
$2.03
$0.39
$1.02
$0.10
$0.52
$0.72
-$0.02
Recent news
Company coverage with links to the original publishers.
AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.
Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.
AbbVie (ABBV) is trending among investors with shares up 4.2% over the past month, outperforming the S&P 500's -3% decline. The pharmaceutical company shows strong earnings growth expectations of +39.7% for the current fiscal year and +14.7% for next year, with a consistent track record of beating consensus estimates. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term. The company is valued at par with its peers based on valuation metrics.
The Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed healthcare sector ETF with $4.08 billion in assets and a low 0.08% expense ratio. Year-to-date performance is up 21.32%, with top holdings including Eli Lilly, Johnson & Johnson, and Abbvie. The ETF carries a Zacks ETF Rank of 3 (Hold) and offers medium-risk diversified exposure to 348 healthcare companies.
Commit Biologics completed a $60 million seed financing round led by Ackermans & van Haaren, with participation from AbbVie Ventures and M Ventures. The funds will support IND-enabling activities and clinical development of COM002, its first development candidate, a dual-targeting bispecific complement engager designed for cancer and autoimmune disease treatment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$1.82 per share
Declared
Oct 29, 2026
Ex-dividend
Jan 15, 2027
Pay date
Feb 16, 2027
Ex-dividend
Amount / share
Pay date
Type
Oct 15, 2026
$1.73
Nov 16, 2026
recurring
Jul 15, 2026
$1.73
Aug 14, 2026
recurring
Apr 15, 2026
$1.73
May 15, 2026
recurring
Jan 16, 2026
$1.73
Feb 17, 2026
recurring
Oct 15, 2025
$1.64
Nov 14, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.